ReviewPharmaceutics2024
Plant-Derived Vesicle-like Nanoparticles: The Next-Generation Drug Delivery Nanoplatforms.
Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The expanding role of biocompatible hydrogels in plant-derived exosome-like nanovesicles for skin diseases: prospects and challenges.Annals of medicine · 2026Review
- Green nanomedicine for cancer therapy.Chinese medical journal · 2026Review
- Plant-derived nanovesicles: the intelligent nanoplatforms for therapeutics and drug delivery.Journal of nanobiotechnology · 2026Review
- Salvia miltiorrhiza-Derived Vesicle-Like Nanoparticles Functionalised Hydrogel With Excellent Ability of Oxidative Stress Modulation and Anti-Cardiomyocyte Apoptosis for Sepsis-Induced Myocardial Injury.Plant biotechnology journal · 2026Article
- Edible Plant-Derived Exosome-like Nanoparticles as Prebiotic Nanocarriers: Gut Microbiota Modulation and Functional Food Potential.Pharmaceutics · 2026Review
- Plant-derived nanocarriers & nanostructures for barrier-defined translation: a comprehensive review of mechanisms, targets, and translation.Journal of nanobiotechnology · 2026Review
- Plant-derived extracellular vesicles as tools and targets for inflammatory diseases.Journal of nanobiotechnology · 2026Review
- Extracellular vesicles derived from Citrus plants: innovative applications in therapeutics and drug delivery.Journal of nanobiotechnology · 2026Review
- Exosome-Inspired Nanocarriers in Cancer Therapy: Bio-Derived Nanotechnology Meets Nano Drug Delivery.International journal of nanomedicine · 2026Review
- Plant-Derived Extracellular-Vesicle-Like Particles: Immune Regulation and Disease Therapy.Research (Washington, D.C.) · 2026Review
- Engineered plant extracellular vesicles: Emerging nanoplatforms for combinational cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- Plant-derived vesicle-like nanoparticles in food crops: emerging insights into nutritional biofortification and biomedical applications.Plant biotechnology journal · 2025Review
- Exosomes derived from Panax notoginseng promote osteogenic differentiation of rBMSCs via the PI3K/AKT signaling pathway.Frontiers in pharmacology · 2025Article
- Recent Advances in Plant-Derived Extracellular Vesicles as Nanoparticles for Cancer Drug Delivery.International journal of nanomedicine · 2025Review
- Emerging Role of Plant-Derived Nanostructures in Nanomedicine.International journal of nanomedicine · 2025Review
- Plant-derived vesicles: isolation strategies and therapeutic applications.Frontiers in plant science · 2025Review
- Plant-Derived Exosome-Like Nanovesicles: A Novel Strategy for Targeted Oral Therapy in Ulcerative Colitis.International journal of nanomedicine · 2025Review
- Unveiling the dynamic trends of plant-derived exosome nanovesicles-based theranostics: through bibliometric and visualized analysis.Frontiers in medicine · 2025Article
- Leveraging plant-derived nanovesicles for advanced nucleic acid-based gene therapy.Theranostics · 2025Review
- Exosomes in Disease Therapy: Plant-Derived Exosome-Like Nanoparticles Current Status, Challenges, and Future Prospects.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A wide variety of natural bioactive compounds derived from plants have demonstrated significant clinical relevance in the treatment of various diseases such as cancer, chronic disease, and inflammation. An increasing number of studies have surfaced that give credence to the potential of plant-derived vesicle-like nanoparticles (PDVLNs) as compelling candidates for a drug delivery system (DDS). PDVLNs are cost-effective production, non-toxicity and non-immunogenicity and fascinating bi-ocompatibility. In this review, we attempt to comprehensively review and consolidate the position of PDVLNs as next-generation drug delivery nanoplatforms. We aim to give a quick glance to readers of the current developments of PDVLNs, including their biogenesis, characteristic features, composition, administration routes, advantages, and application. Further, we discuss the advantages and limitations of PDVLNs. We expect that the role of PDVLNs in drug delivery will be significantly enhanced, thus positioning them as the next generation of therapeutic modalities in the foreseeable future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.